HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future

Luciano Mariani, Aldo Venuti, Luciano Mariani, Aldo Venuti

Abstract

Although long-term protection is a key-point in evaluating HPV-vaccine over time, there is currently inadequate information on the duration of HPV vaccine-induced immunity and on the mechanisms related to the activation of immune-memory. Longer-term surveillance in a vaccinated population is needed to identify waning immunity, evaluating any requirements for booster immunizations to assess vaccine efficacy against HPV-diseases. Current prophylactic vaccines have the primary end-points to protect against HPV-16 and 18, the genotypes more associated to cervical cancer worldwide. Nevertheless, data from many countries demonstrate the presence, at significant levels, of HPVs that are not included in the currently available vaccine preparations, indicating that these vaccines could be less effective in a particular area of the world. The development of vaccines covering a larger number of HPVs presents the most complex challenge for the future. Therefore, long term immunization and cross-protection of HPV vaccines will be discussed in light of new approaches for the future.

References

    1. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14–9.
    1. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. Survey of HPV in Ontario Women Group. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168:421–5.
    1. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1808–16. doi: 10.1086/428779.
    1. Castellsagué Xavier, Achim Schneider, Andreas M, Kaufmann b, Bosch F Xavier. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3 Suppl):S15–23. doi: 10.1016/j.ygyno.2009.09.021.
    1. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–4333. doi: 10.1016/j.vaccine.2007.02.069.
    1. David MP, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol. 2009;115(3 Suppl):S1–6. doi: 10.1016/j.ygyno.2009.01.011. Epub 2009 Feb 12.
    1. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, Pfister H, Tay SK, ter Meulen J, Villa LL. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol. 1993;67:6424–31.
    1. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst. 2006;98:1045–52. doi: 10.1093/jnci/djj297.
    1. Bernard Hans-Ulrich, Itzel Calleja-Macia E, Dunn S Terence. Genome variation of human papillomavirus types: Phylogenetic and medical Implications. Int J Cancer. 2006;118:1071–1076. doi: 10.1002/ijc.21655.
    1. Frazer I. Correlating immunity with protection for HPV infection. Int J Infectious Dis. 2007;11(Supplement 2):S10–S16. doi: 10.1016/S1201-9712(07)60016-2.
    1. Einstein M, Schiller JT, Viscidi RP, Strickler H, Coursaget P, Tan T, Halsey N, Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9:347–56. doi: 10.1016/S1473-3099(09)70108-2.
    1. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, Celentano D, Smith JS. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer. 2006;119:1623–9. doi: 10.1002/ijc.22015.
    1. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;8:209–20.
    1. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, Taylor-Robinson D, Stanley MA. Immunological events in regressing genital warts. Am J Clin Pathol. 1994;102:768–774.
    1. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, Stanley MA. Regression of canine oral papillomas is associated with infiltration of CD4þ and CD8þ lymphocytes. Virology. 2001;283:31–39. doi: 10.1006/viro.2000.0789.
    1. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9. doi: 10.1086/315498.
    1. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002;169:3242–9.
    1. Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003;63:3478–82.
    1. Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer. 2004;91:1269–1274. doi: 10.1038/sj.bjc.6602088.
    1. Ferris D, Garland S, for the Quadrivalent HPV Vaccine Investigators. Evaluation of quadrivalent hpv 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with prior vaccine hpv type infection. The 13th International Congress on Infectious Diseases Kuala Lumpur, Malaysia; 2008.
    1. WHO position paper, No. 15. 2009. pp. 118–132.
    1. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24:5571–83. doi: 10.1016/j.vaccine.2006.04.068.
    1. Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine) Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer. Tampa; 2008. Mar 9-12.
    1. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–68. doi: 10.1016/S0140-6736(07)60852-6.
    1. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin GG. for the HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70. doi: 10.1016/S0140-6736(07)60946-5.
    1. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner S, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki F, Schwarz T, Poppe W, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study inyoung women. Lancet. 2009;374:301–14. doi: 10.1016/S0140-6736(09)61248-4.
    1. Schwarz T, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature. Gynecol Oncol. 2008;110:S1–S10. doi: 10.1016/j.ygyno.2008.05.036.
    1. David Jenkins. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008;110:S18–S25. doi: 10.1016/j.ygyno.2008.06.027.
    1. Joura E, Kjaer S, Wheeler C, Sigurdssond K, Iversen OE, Hernandez-Avila M, Perez G, Brown D, Koutsky L, Hseon Tay E, García P, Ault K, Garland S, Leodolter S, Olsson SE, Tango G, Ferris D, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman R, Majewski S, Munoz N, Myers E, Villa LL, Taddeo F, Roberts C, Tadesse A, Bryan J, Lupinacci L, Giacoletti K, Lu S, Vuocolo S, Hesley T, Haupt R, Barr EH. PV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26:6844–6851. doi: 10.1016/j.vaccine.2008.09.073.
    1. Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines. 2005;4(4):459–71. doi: 10.1586/14760584.4.4.459.
    1. Stanley M, Moore RA, Nicholls PK, Santos EB, Thomsen L, Parry N, Walcott S, Gough G. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPVin beagle dogs. Vaccine. 2001;19:2783–92. doi: 10.1016/S0264-410X(00)00533-8.
    1. Margaret Stanley. Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 2008;109:S15–S21. doi: 10.1016/j.ygyno.2008.02.003.
    1. GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975–85. doi: 10.1016/S0140-6736(09)61567-1.
    1. Paolini F, Venuti A. Other good news from prophylactic HPV vaccines: long-term duration of immunity. Womens Health (Lond Engl) 2010;6:361–3.
    1. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity. Lancet. 2002;355:561–5. doi: 10.1016/S0140-6736(99)07239-6.
    1. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol. 2007;107:S27–S30. doi: 10.1016/j.ygyno.2007.07.078.
    1. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau Marc A, Colau Brigitte, Suzich Joann, Losonksy Genevieve, Martin Marie-Thérèse, Gary Dubin, Wettendorff Martine A. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937–49. doi: 10.1016/j.vaccine.2006.06.005.
    1. Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F, Carletti I, Dessy F, Trofa A, Schuind A. Dubin G on behalf of the HPV-010 Study Group. Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines. 2009;5(10):1–15. doi: 10.4161/hv.5.10.9518.
    1. WHO. Guidelines to assure the quality, safety and efficacy of recombinant HPV virus-like particle vaccines. 2006.
    1. Olsson SE, Villa LL, Costa R, Petta C, Andrade R, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Lehtinen M, Paavonen J, Tamms G, Giacoletti K, Lupinacci L, Esser M, Vuocolo S, Saah A, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931–4939. doi: 10.1016/j.vaccine.2007.03.049.
    1. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, Changchien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol. 2006;101:40–45. doi: 10.1016/j.ygyno.2005.09.028.
    1. Miyashita M, Agdamag DM, Sasagawa T, Matsushita L, Salud LM, Salud CO, Saikawa K, Leano PS, Pagcaliwagan T, Acuna J, Ishizaki A, Kageyama S, Ichimura H. High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. J Med Virol. 2009;81:545–551. doi: 10.1002/jmv.21416.
    1. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ, Rha SH, Jung SI, Kim JI, Jung KY, Van Doorn LJ, Quint W. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis. 2004;190:468–476. doi: 10.1086/421279.
    1. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006;6:753–763. doi: 10.1038/nrc1973.
    1. Brown D, Kjaer S, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler C, Perez G, Koutsky L, Hseon Tay E, Garcia P, Ault K, Garland S, Leodolter S, Olsson SE, Tang G, Ferris D, Paavonen J, Steben M, Bosch FX, Dillner J, Joura E, Kurman R, Majewski S, Muñoz N, Myers E, Villa LL, Taddeo F, Roberts C, Tadesse A, Bryan J, Lupinacci L, Giacoletti K, Sings H, James M, Hesley T, Bar E. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. JID. 2009;199:926–35. doi: 10.1086/597307.
    1. Wheeler C, Kjaer S, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown D, Koutsky L, Hseon Tay E, García P, Ault K, Garland S, Leodolter S, Olsson SE, Tang G, Ferris G, Paavonen J, Steben M, Bosch FX, Dillner J, Joura E, Kurman R, Majewski R, Muñoz N, Myers ER, Villa LL, Taddeo F, Roberts C, Tadesse A, Bryan J, Lupinacci L, Giacoletti K, James M, Vuocolo S, Hesley T, Bar E. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. JID. 2009;199:936–44. doi: 10.1086/597309.
    1. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008;110:S18–S25. doi: 10.1016/j.ygyno.2008.06.027.
    1. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol. 1993;74:945–953. doi: 10.1099/0022-1317-74-6-945.
    1. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibodyinducing neutralizing epitopes. Virology. 1991;181:572–579. doi: 10.1016/0042-6822(91)90890-N.
    1. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol. 2002;76:9798–9805. doi: 10.1128/JVI.76.19.9798-9805.2002.
    1. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol. 1996;77:1577–1583. doi: 10.1099/0022-1317-77-7-1577.
    1. McGarvie GM, Chandrachud LM, Gaukroger J, Grindlay GJ, O'Neil BW, Baird JW, Wagner ER, Jarrett WFH, Campo MS. In: Papillomavirus immunology. Stanley MA, editor. Plenum Publishing Corporation, New York, NY; 1994. Vaccination of cattle with L2 protein prevents BPV-4 infection; pp. 283–290.
    1. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology. 1992;187:612–619. doi: 10.1016/0042-6822(92)90463-Y.
    1. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RBS. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol. 2007;81(21):11585–92. doi: 10.1128/JVI.01577-07. Epub 2007 Aug 22.
    1. Pastrana DV, Gambhira R, Buck CB, Pang Y-YS, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RBS. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005;337:365–372. doi: 10.1016/j.virol.2005.04.011.
    1. Gambhira R, Gravitt P, Bossis I, Stern P, Viscidi RP, Roden R. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res. 2006;66:11120–11124. doi: 10.1158/0008-5472.CAN-06-2560.
    1. Liu WJ, Gissmann L, Sun Y, Kanjanahaluethai A, Muller M, Doorbar J, Zhou J. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology. 1997;227:474–483. doi: 10.1006/viro.1996.8348.
    1. Day P, Gambhira R, Roden R, Lowy D, Schiller J. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol. 2008;82:4638–4646. doi: 10.1128/JVI.00143-08.
    1. Day P, Lowy D, Schiller J. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol. 2008;82:12565–12568. doi: 10.1128/JVI.01631-08.
    1. Slupetzky K, Gambhira R, Culp T, Shafti-Keramat S, Schellenbacher C, Christensen N, Roden R, Kirnbauer R. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine. 2007;25:2001–2010. doi: 10.1016/j.vaccine.2006.11.049.
    1. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Muller M, Ottonello S. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine. pp. 1949–1956.
    1. Alphs H, Gambhira R, Karanam B, Roberts J, Jagu S, Schiller J, Zeng W, Jackson D, Roden R. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA. 2008;105:5850–5855. doi: 10.1073/pnas.0800868105.
    1. Jagu S, Karanam B, Gambhira R, Chivukula S, Chaganti R, Lowy D, Schiller J, Roden R. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009;101:782–792. doi: 10.1093/jnci/djp106.
    1. Yuan H, Estes P, Chen Y, Newsome Y, Olcese V, Garcea R, Schlegel R. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol. 2001;75:7848–7853. doi: 10.1128/JVI.75.17.7848-7853.2001.
    1. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol. 2004;78:12901–12909. doi: 10.1128/JVI.78.23.12901-12909.2004.
    1. Fraillery D, Baud D, Pang S, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007;14:1285–1295. doi: 10.1128/CVI.00164-07.
    1. Franconi R, Venuti A. In: Papillomavirus research: from Natural History to Vaccines and Beyond. Saveria Campo M, editor. Norfolk, U.K.: Caister Academic Press; 2006. HPV Vaccines in Plants: an appetising solution to Control Infection and Associated Cancers; pp. 357–372.
    1. Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discov Today. 2009;14(1-2):16–24. doi: 10.1016/j.drudis.2008.10.002. Epub 2008 Nov 18.
    1. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol. 2003;77:9211–9220. doi: 10.1128/JVI.77.17.9211-9220.2003.
    1. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch Virol. 2003;148:1771–1786. doi: 10.1007/s00705-003-0119-4.
    1. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL, Clements JD, Rose RC. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol. 2003;77:8702–8711. doi: 10.1128/JVI.77.16.8702-8711.2003.
    1. Fernandez-San Millan A, Ortigosa SM, Hervás-Stubbs S, Corral-Martínez P, Seguí-Simarro JM, Gaétan J, Coursaget P, Veramendi J. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J. 2008;6:427–441. doi: 10.1111/j.1467-7652.2008.00338.x.
    1. Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J. 2009;6:6–2. doi: 10.1186/1743-422X-6-6.
    1. Mariani L. HPV-vaccine and screening programs: the new era of global prevention. J Prev Med Hyg. 2009;50(2):90–5.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel